European Prostate Cancer Screening After 23 Years: Sustained Mortality Reduction and Improved Harm-Benefit Profile
Highlight
– PSA screening leads to a 13% reduction in prostate cancer mortality after 23 years.
– Absolute risk reduction is 0.22%, indicating a small but meaningful benefit.
– Screening increases prostate cancer diagnosis by 30%, reflecting overdiagnosis.
– One prostate cancer death is prevented for every 456 men invited to screening.
– Improved harm-benefit ratio suggests more targeted, risk-based screening is warranted.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.